HeartBeam (NASDAQ: BEAT) was featured among a select group of medical device companies in a January industry roundup highlighting recent U.S. Food and Drug Administration (FDA) clearances and approvals across the sector, according to a press release issued by the company. The recognition underscores HeartBeam’s progress as it advances a novel approach to cardiac diagnostics through its HeartBeam System, a cable-free, high-fidelity ECG platform designed to capture the heart’s electrical signals from three distinct directions and synthesize them into a 12-lead ECG for arrhythmia assessment.
The company was included in a report published by Modern Healthcare and authored by Lauren Dubinsky, which examined recent FDA activity across the medical device landscape. The report highlighted companies that achieved meaningful regulatory milestones or demonstrated forward momentum entering the new year. HeartBeam was included as part of this broader discussion of innovation and regulatory progress within the sector, reflecting growing attention on technologies aimed at improving access to clinical-grade data outside of traditional healthcare settings.
HeartBeam is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The company is creating the first-ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care - all outside of a medical facility, thus redefining the future of cardiac health management. The company holds 13 U.S. and 4 international-issued patents related to technology enablement.
The inclusion in the Modern Healthcare article is significant because it validates HeartBeam's regulatory progress and positions the company among peers that are driving innovation in medical devices. For further details, the full article can be viewed at https://nnw.fm/1nd5y. More information about HeartBeam is available on its website at www.HeartBeam.com. The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT.
Forward-looking statements in the press release are subject to risks and uncertainties, including those set forth under the heading "Risk Factors" in the company's most recent Annual Report on Form 10-K and subsequent filings with the SEC.
